Submissions for variant NM_001042492.3(NF1):c.5488C>T (p.Arg1830Cys)

gnomAD frequency: 0.00001  dbSNP: rs797045139

Total submissions: 28

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
GeneDx	RCV000439869	SCV000521065	pathogenic	not provided	2020-01-02	criteria provided, single submitter	clinical testing	p.Arg1809 missense variants account for approximately 1% of individuals with neurofibromatosis type 1 (Rojnueangnit et al., 2015); Not observed in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 27322474, 12807981, 26457592, 25533962, 27171602, 28135719, 19120036, 24789688, 28191890, 29522274, 18183640, 24357598, 26178382, 31730495, 31717729, 31370276, 32107864, 33482836, 32427313, 31785789, 25966637, 25370043)
Invitae	RCV000190889	SCV000542189	pathogenic	Neurofibromatosis, type 1	2024-01-11	criteria provided, single submitter	clinical testing	This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 1809 of the NF1 protein (p.Arg1809Cys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with neurofibromatosis, neurofibromatosis-Noonan syndrome, and/or Noonan syndrome (PMID: 12807981, 19120036, 24357598, 24789688, 26178382). It has also been observed to segregate with disease in related individuals. This missense change has been observed in at least one individual who was not affected with NF1-related conditions (PMID: 12807981, 19120036). ClinVar contains an entry for this variant (Variation ID: 208853). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt NF1 protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic.
Center for Human Genetics, Inc, Center for Human Genetics, Inc	RCV000190889	SCV000782050	pathogenic	Neurofibromatosis, type 1	2016-11-01	criteria provided, single submitter	clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories	RCV000999745	SCV000885839	pathogenic	not specified	2019-04-01	criteria provided, single submitter	clinical testing	The NF1 c.5488C>T;p.Arg1830Cys variant (also known as c.5425C>T;p.Arg1809Cys) is published in the medical literature in multiple individuals and families with neurofibromatosis type-1, described as mild or atypical as many do not exhibit Lisch nodules and no individuals were described with cutaneous or plexiform neurofibromas, NF1 osseous lesions or symptomatic optic gliomas (Ekvall 2014, Pinna 2015, Rojnueagnit 2015, Santoro 2015). Additionally, other variants in this codon are also associated with a mild or atypical NF1 (Rojnueagnit 2015, Santoro 2015). The c.5488C>T variant is listed in the ClinVar database (Variation ID: 208853) and the dbSNP variant database (rs797045139), but is not listed in the general population-based databases (Exome Variant Server, Genome Aggregation Database). The arginine at this position is well conserved across species and computational algorithms (AlignGVGD, PolyPhen2, SIFT) predict this variant is deleterious. Considering available information, this variant is classified as pathogenic and predicted to produce an atypical phenotype. References: Ekvall S et al. Novel association of neurofibromatosis type 1-causing mutations in families with neurofibromatosis-Noonan syndrome. Am J Med Genet A. 2014 Mar;164A(3):579-87. Pinna V et al. p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas. Eur J Hum Genet. 2015 Aug;23(8):1068-71. Rojnueangnit K et al. High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype Correlation. Hum Mutat. 2015 Nov;36(11):1052-63. Santoro C et al. Arg(1809) substitution in neurofibromin: further evidence of a genotype-phenotype correlation in neurofibromatosis type 1. Eur J Hum Genet. 2015 Nov;23(11):1460-1.
Ambry Genetics	RCV002319460	SCV001186043	pathogenic	Hereditary cancer-predisposing syndrome; Cardiovascular phenotype	2021-03-17	criteria provided, single submitter	clinical testing	The p.R1809C pathogenic mutation (also known as c.5425C>T), located in coding exon 37 of the NF1 gene, results from a C to T substitution at nucleotide position 5425. The arginine at codon 1809 is replaced by cysteine, an amino acid with highly dissimilar properties. This alteration was detected in an individual with sporadic neurofibromatosis type 1 (NF1), but was reported to be also observed in unaffected relatives (Ars E et al. J. Med. Genet. 2003; 40:e82). However, a recent study has re-evaluated the family and confirmed that all members with this alteration were affected (Rojnueangnit K et al. Hum. Mutat. 2015 Nov;36:1052-63). This alteration was then described in another proband with features of Noonan/NF1 harboring both this variant and a de novo PTPN11 alteration. Several members of the family were affected with cafe-au-lait spots, but the NF1 variant did not segregate with this feature (Nyström AM et al. Acta Paediatr. 2009; 98:693-8). Moreover, this alteration has also been reported in multiple families exhibiting mild forms of NF1, and to either occur de novo or segregate with the disease in a few cases (Ekvall S et al. Am. J. Med. Genet. A 2014; 164:579-87; Pinna V et al. Eur. J. Hum. Genet. 2015 Aug;23:1068-71; Santoro C et al. Eur. J. Hum. Genet. 2015 Nov;23:1460-1; Bianchessi D et al. Mol Genet Genomic Med. 2015 Nov;3:513-25; Rojnueangnit K et al. Hum. Mutat. 2015 Nov;36:1052-63). In two studies, authors described a unique phenotype seen in individuals with alterations located at p.R1809 consisting of: cafe au lait spots, skinfold freckling, Noonan-like features, and developmental delays, but not cutaneous or plexiform neurofibromas lisch nodules, osseous lesions or symptomatic optic gliomas (Shofty B et al. Semin Pediatr Neurol. 2015 Dec;22:234-9; Rojnueangnit K et al. Hum. Mutat. 2015 Nov;36:1052-63). This alteration was also detected on whole-exome sequencing n a pediatric patient with multiple cafe-au-lait spots, acanthosis nigricans, action tremor, facial palsy, degeneration of anterior horn cells, atrophy/degeneration involving motor neurons, and progressive muscle weakness (Deciphering Developmental Disorders Study. Nature. 2015 Mar;519:223-8). Based on the available evidence, p.R1809C is classified as a pathogenic mutation.
Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago	RCV001027793	SCV001190403	pathogenic	Neurofibromatosis, familial spinal; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis	2019-06-26	criteria provided, single submitter	clinical testing	NF1 NM_000267.3 exon 37 p.Arg1809Cys (c.5425C>T): This variant has been reported in the literature in several individuals with multiple cafe-au-lait spots, some who also presented with features consistent with Noonan syndrome (such as dysmorphic facies and mild intellectual disability), but none with neurofibromas or typical osseous lesions consistent with NF1 (Ekvall 2014 PMID:24357598, Xu 2014 PMID:24789688, Fitzgerald 2015 PMID:25533962, Pinna 2015 PMID:25370043, Rojneuangnit 2015 PMID:26178382, Santoro 2015 PMID:25966637). Therefore, this variant is suggested to be associated with a mild/atypical neurofibromatosis phenotype. This variant has also been reported multiple times in the LOVD NF1 database (https://databases.lovd.nl/shared/genes/NF1). This variant is not present in large control databases but is present in ClinVar, with several labs classifying this variant as pathogenic (Variation ID:208853). Evolutionary conservation and computational predictive tools suggest that this variant may impact the protein. In addition, functional studies have demonstrated decreased GTP-RAS levels with this variant (Wallis 2018 PMID:29522274). However, these studies may not accurately represent in vivo biological function. Several additional variants at the same amino acid residue (Arg1809Gly, Arg1809Ser, Arg1809Pro, Arg1809Leu) have been reported in individuals with mild neurofibromatosis type 1, further supporting the functional relevance of this codon. In summary, this variant is classified as pathogenic based on the data above.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV000190889	SCV001361018	pathogenic	Neurofibromatosis, type 1	2019-07-31	criteria provided, single submitter	clinical testing	Variant summary: NF1 c.5425C>T (p.Arg1809Cys) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251906 control chromosomes (gnomAD and publication). c.5425C>T has been reported in the literature in multiple individuals affected with Neurofibromatosis Type 1 (NF1) (Syrbe_2007, Ekvall_2013, Pinna_2015) and Neurofibromatosis-Noonan Syndrome (NFNS) (Ekvall_2013). Authors indicate the variant to cause a mild form presenting with cafe au lait spots with or without freckling or Lisch nodules and no neurofibromas. In addition, one family showed lack of segregation with disease (Nystrom_2008). These data indicate that the variant is very likely to be associated with disease. A functional study, Wallis_2018, found the variant to lower GTP-RAS levels similar to the wild-type protein, but was unable to repress p-ERK/ERK and ELK1 transcriptional activity. Four ClinVar submissions (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Diagnostic Laboratory, Strasbourg University Hospital	RCV001257603	SCV001434413	pathogenic	Intellectual disability	2020-04-20	criteria provided, single submitter	clinical testing
Genome Diagnostics Laboratory, The Hospital for Sick Children	RCV000190889	SCV001479024	pathogenic	Neurofibromatosis, type 1	2020-10-26	criteria provided, single submitter	clinical testing
CeGaT Center for Human Genetics Tuebingen	RCV000439869	SCV001500115	pathogenic	not provided	2022-09-01	criteria provided, single submitter	clinical testing	NF1: PM2, PM5, PS4:Moderate, PM6:Supporting, PP1, PP2, PP3, PP4
3billion	RCV001775095	SCV002012193	pathogenic	Neurofibromatosis-Noonan syndrome	2021-10-02	criteria provided, single submitter	clinical testing	Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic in similarly affected unrelated individuals (PMID:22729224,26520804, 28502725, 29522274 PS4). It is not observed in the gnomAD v2.1.1 dataset (PM2). A different missense change at the same codon (p.Arg1830Ser, p.Arg1830Gly, and p.Arg1830Leu) has been reported as pathogenic (PM5). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.919, 3Cnet: 0.980, PP3). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline.
Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center	RCV001775095	SCV002061846	pathogenic	Neurofibromatosis-Noonan syndrome	2021-04-27	criteria provided, single submitter	clinical testing	PS4, PP2, PP3, PM2, PS3_Moderate, PM5, PM6
Centre de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille	RCV002273979	SCV002559004	pathogenic	Neurodevelopmental delay		criteria provided, single submitter	clinical testing
Genome-Nilou Lab	RCV000190889	SCV002560120	pathogenic	Neurofibromatosis, type 1	2022-03-15	criteria provided, single submitter	clinical testing
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute	RCV001775095	SCV002766618	pathogenic	Neurofibromatosis-Noonan syndrome	2022-03-31	criteria provided, single submitter	clinical testing	Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with neurofibromatosis-Noonan syndrome (MIM#601321). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0115 - Variants in this gene are known to have variable expressivity (PMID: 20301288). (I) 0200 - Variant is predicted to result in a missense amino acid change from arginine to cysteine. (I) 0251 - This variant is heterozygous. (I) 0302 - Variant is present in gnomAD (v3) <0.001 for a dominant condition (1 heterozygote, 0 homozygotes). (SP) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0600 - Variant is located in the annotated pleckstrin homology domain (PMID: 26178382). (I) 0701 - Other missense variants comparable to the one identified in this case have very strong previous evidence for pathogenicity. Four alternative changes at this residue have been reported in over ten individuals with neurofibromatosis (PMID: 26178382). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant is a well-reported pathogenic variant known to cause neurofibromatosis and neurofibromatosis-Noonan syndrome (ClinVar, PMID: 26178382). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute	RCV000190889	SCV002768631	pathogenic	Neurofibromatosis, type 1	2020-05-21	criteria provided, single submitter	clinical testing	A heterozygous missense variant was identified, NM_000267.3(NF1):c.5425C>T in exon 37 of 57 of the NF1 gene. (NB: this variant is non-coding in alternative transcript, NM_001128147.3). This substitution is predicted to create a major amino acid change from an arginine to a cysteine at position 1809 of the protein; NP_000258.1(NF1):p.(Arg1809Cys). The arginine at this position has very high conservation (100 vertebrates, UCSC), and is located within a constrained region of the alpha-helix of the Pleckstrin Homology domain (Rojnueangnit, K. et al. (2015)). In silico software predicts this variant to be damaging (Polyphen, SIFT, CADD, Mutation Taster). The variant is not present in the gnomAD population database. This variant has been previously reported as pathogenic in patients with Neurofibromatosis type 1 and Neurofibromatosis-Noonan syndrome (ClinVar). Five different missense variants in the same codon p.Arg1809, have been shown to cause a specific phenotype of multiple cafe-au-lait macules (CALM), with or without skinfold freckling and Lisch nodules (ClinVar, Rojnueangnit, K. et al. (2015)). Based on information available at the time of curation, this variant has been classified as PATHOGENIC.
Fulgent Genetics, Fulgent Genetics	RCV002503749	SCV002810380	pathogenic	Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis	2021-10-22	criteria provided, single submitter	clinical testing
Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago	RCV002503749	SCV003920276	pathogenic	Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis	2021-03-30	criteria provided, single submitter	clinical testing	NF1 NM_000267.3 exon 37 p.Arg1809Cys (c.5425C>T): This variant has been reported in the literature in several individuals with multiple cafe-au-lait spots, some who also presented with features consistent with Noonan syndrome (such as dysmorphic facies and mild intellectual disability), but none with neurofibromas or typical osseous lesions consistent with NF1 (Ekvall 2014 PMID:24357598, Xu 2014 PMID:24789688, Fitzgerald 2015 PMID:25533962, Pinna 2015 PMID:25370043, Rojneuangnit 2015 PMID:26178382, Santoro 2015 PMID:25966637). Therefore, this variant is suggested to be associated with a mild/atypical neurofibromatosis phenotype. This variant has also been reported multiple times in the LOVD NF1 database (https://databases.lovd.nl/shared/genes/NF1). This variant is not present in large control databases but is present in ClinVar, with several labs classifying this variant as pathogenic (Variation ID:208853). Evolutionary conservation and computational predictive tools suggest that this variant may impact the protein. In addition, functional studies have demonstrated decreased GTP-RAS levels with this variant (Wallis 2018 PMID:29522274). However, these studies may not accurately represent in vivo biological function. Several additional variants at the same amino acid residue (Arg1809Gly, Arg1809Ser, Arg1809Pro, Arg1809Leu) have been reported in individuals with mild neurofibromatosis type 1, further supporting the functional relevance of this codon. In summary, this variant is classified as pathogenic based on the data above.
PreventionGenetics, part of Exact Sciences	RCV004553045	SCV004119996	pathogenic	NF1-related disorder	2023-12-20	criteria provided, single submitter	clinical testing	The NF1 c.5488C>T variant is predicted to result in the amino acid substitution p.Arg1830Cys. This variant has been well documented to be causative for NF1-related disorders in both de novo and familial cases (alternate nomenclature p.Arg1809Cys; Rojnueangnit et al. 2015. PubMed ID: 26178382; Ekvall et al. 2014. PubMed ID: 24357598; Bianchessi et al. 2015. PubMed ID: 26740943; Santoro et al. 2015. PubMed ID: 25966637; Pinna et al. 2015. PubMed ID: 25370043). Functional studies and familial segregation data both support its pathogenicity (Wallis et al. 2018. PubMed ID: 29522274; Long et al. 2022. PubMed ID: 34694046; Rojnueangnit et al. 2015. PubMed ID: 26178382). This variant has not been reported in a large population database, indicating this variant is rare. In ClinVar, this variant has been interpreted as pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/208853/). This variant is interpreted as pathogenic.
Baylor Genetics	RCV003468878	SCV004190796	pathogenic	Juvenile myelomonocytic leukemia	2022-07-20	criteria provided, single submitter	clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano	RCV000439869	SCV004222176	likely benign	not provided	2012-07-17	criteria provided, single submitter	clinical testing
Mayo Clinic Laboratories, Mayo Clinic	RCV000439869	SCV004224694	pathogenic	not provided	2022-06-20	criteria provided, single submitter	clinical testing	PP1_strong, PP2, PP3, PP4, PP5, PM2, PM6_very_strong, PS4_moderate
Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center	RCV000190889	SCV004805280	uncertain significance	Neurofibromatosis, type 1	2024-03-25	criteria provided, single submitter	research
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000190889	SCV004848086	pathogenic	Neurofibromatosis, type 1	2017-07-24	criteria provided, single submitter	clinical testing	The p.Arg1830Cys (also referred to as p.Arg1809Cys on NM_000267.3) variant in NF1 has been reported in >80 probands with clinical features of neurofibromatosis type 1 (NF1) or Noonan syndrome-NF1 syndrome and segregated with disease in >40 relatives (Ars 2003, Nystrom 2008, Ekvall 2014, Rojnueangnit 2015, Pinna 2015, Santoro 2015). Most patients with this variant have a milder form of NF1, with skin abnormalities but no neurofibromas or tumors aside from lipomas in some individuals. In some families, however, cafe au lait spots were present in relatives who did not have the variant (Nystrom 2008, Rojnueangnit 2015). This variant has also been reported in ClinVar (Variation ID# 208853). Computational prediction tools and conservation analysis suggest that the p.Arg1830Cys variant may impact the protein. In summary, this variant meets criteria to be classified as pathogenic for NF1 in an autosomal dominant manner but is expected to result in a milder phenotype.
Medical Genomics Laboratory, Department of Genetics UAB	RCV000190889	SCV000245763	pathogenic	Neurofibromatosis, type 1		no assertion criteria provided	clinical testing
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+	RCV000439869	SCV002037223	pathogenic	not provided		no assertion criteria provided	clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center	RCV000439869	SCV002037696	pathogenic	not provided		no assertion criteria provided	clinical testing
GeneReviews	RCV000190889	SCV002064275	not provided	Neurofibromatosis, type 1		no assertion provided	literature only